作者
Michael Farrell, Jeyran Shahbazi, Mark Chambers, Marianne Byrne, Jaleh Gholami, Emma Zahra, Jason Grebely, Nicholas Lintzeris, Briony Larance, Robert Ali, Suzanne Nielsen, Adrian Dunlop, Gregory J Dore, Michael McDonough, Mark Montebello, Rob Weiss, Craig Rodgers, Jon Cook, Louisa Degenhardt, CoLAB study team
发表日期
2024/5/1
期刊
International Journal of Drug Policy
卷号
127
页码范围
104390
出版商
Elsevier
简介
Background
The most recent formulation of buprenorphine treatment is extended-release depot injections (BUP-XR) that are administered subcutaneously by health care professionals. This study aimed to observe treatment outcomes of BUP-XR delivered in standard practice during a 96-week follow-up period in a community setting.
Methods
This study is an extension of the CoLAB study, a prospective single-arm, multicentre, open label trial (N=100, 7 sites in Australia) among people with opioid dependence who received monthly injections of BUP-XR to evaluate the retention in treatment. Participants were followed for 96 weeks, comprising 48 weeks of the CoLAB study followed by a 48-week extension.
Results
Of 100 participants at baseline, 47 were retained on BUP-XR at 96 weeks. The median time retained on monthly depot was 90 weeks. Heroin use (adjusted OR=0.19, P=0.012) in the month prior to baseline …
学术搜索中的文章
M Farrell, J Shahbazi, M Chambers, M Byrne… - International Journal of Drug Policy, 2024